Abstract: Ischemic heart disease is the main cause of death and morbidity in most industrialized countries. Stem-and progenitor cell-based treatment approaches for ischemic heart disease are therefore an important frontier in cardiovascular and regenerative medicine. Experimental studies have shown that bone-marrow-derived stem cells and endothelial progenitor cells can improve cardiac function after myocardial infarction, clinical phase I and II studies were rapidly initiated to translate this concept into the clinical setting. However, as of now the effects of stem/progenitor cell administration on cardiac function in the clinical setting have not met expectations. Thus, a better understanding of causes of the current limitations of cell-based therapies is urgently required. Importantly, the number and function of endothelial progenitor cells is reduced in patients with cardiovascular risk factors and/or coronary artery disease. These observations may provide opportunities for an optimization of cell-based treatment approaches. This review provides a summary of current evidence for the role and potential of stem and progenitor cells in the pathophysiology and treatment of ischemic heart disease, including the properties, and repair and regenerative capacities of various stem and progenitor cell populations. In addition, we describe modes of stem/progenitor cell delivery, modulation of their homing as well as potential approaches to "prime" stem/progenitor cells for cardiovascular cell-based therapies. This review provides a summary of the current evidence for the role and potential of stem and progenitor cells in the pathophysiology and treatment of ischemic heart disease, including the properties and repair and regenerative capacities of various stem and progenitor cell populations. In addition, we describe modes of stem/progenitor cell delivery, modulation of their homing as well as potential approaches to "prime" stem/progenitor cells for cardiovascular cell-based therapies. C. Templin et al. 3
Introduction
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used to develop patient-specific stem cells, which could be a unique resource in studying genetic mechanisms of disease development, drug actions, and regenerative biology.
Routes of cell delivery
To date several routes of cell delivery are employed, including (1) The two APOLLO trials aim to evaluate whether adipose tissue-derived cells enhances heart function in acute or chronic ischemia (APOLLO trials).
Further clinical trials are underway investigating the use of c-kit+ cardiac stem cells in patients with chronic ischemic heart disease. Table 1 provides an overview of current ongoing cell therapy trials in patients with myocardial infarction / ischemic cardiomyopathy.
Potential mechanisms mediating effects of adult stem/progenitor cell-based therapy on cardiac function
There are many open questions at present with respect to the understanding of mechanisms of circulating or bone marrow-derived stem/progenitor cell-mediated cardiac repair (Burt et al. 
Limitations of current cell-based treatment approaches
There is currently a limited knowledge on the role of the required number and function of bone marrow cells needed for an optimal effect on cardiac repair. Low cell dosages might in 
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). This is problematic as this cohort is essentially the very one that would need to be treated with progenitor cells. These challenges require further research to enhance the therapeutic efficiency of stem and progenitor cells in the treatment of ischemic heart disease.
This includes the use of more potent cells with a higher cardiac regeneration capacity (for instance induced pluripotent stem cells) and strategies for improving cell homing, survival,, engraftment and repair capacity, of transplanted cells.
Future directions of cell based-therapy for ischemic heart disease
The development of cell-based therapies for ischemic heart disease faces several practical challenges which need to be addressed. Table 1 
